Zai Lab Limited (NASDAQ:ZLAB) ranks among the best high growth Chinese stocks to buy. On January 7, UBS began coverage of Zai Lab Limited (NASDAQ:ZLAB) with a Buy rating and a $35 price target, citing the company’s transition from a China-centric commercial strategy to a global innovation powerhouse. The firm views Zai Lab Limited (NASDAQ:ZLAB) as a distinct biopharma platform poised for long-term global expansion by leveraging its strong China-based business while developing a pipeline of fully owned cancer and immunology assets.
According to UBS, the global pipeline indicates a trend toward high-value, innovative treatments that address numerous unmet needs, potentially redefining Zai Lab’s development path over the coming decade.
The bank believes that Zai Lab Limited (NASDAQ:ZLAB) is undervalued, given recent China commercial disappointments, and that the market doesn’t provide enough credit to its global pipeline, which UBS claims produces considerable long-term value for investors.
Zai Lab Limited (NASDAQ:ZLAB) is a commercial-stage biopharmaceutical company based in China and the United States. It is focused on discovering, developing, and commercializing therapies that address medical conditions with significant unmet needs in oncology, immunology, neuroscience, and infectious disease.
While we acknowledge the potential of ZLAB as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 10 Best Magic Formula Stocks for 2025 and 10 Best Retirement Stocks to Buy According to Hedge Funds.
Disclosure: None. This article is originally published at Insider Monkey.
